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Abstract

Keywords
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Melanoma is one of the most aggressive tumors and its incidence is on the rise. The
low rates of survival in metastatic melanoma has led to the development of new drugs
for this type of patient, such as biological therapy which has shown remarkable results.
This therapy is based on stimulation of the immune system to fight tumoral cells through:
injection of cytokines with immunomodulatory properties (interleukin-2, alphainterferon), vaccination with tumor antigens or immune cells that process tumor
antigens, adoptive immunotherapy, inhibition of immune checkpoints (PD-1, CTLA-4),
inhibition or stimulation of immune modulator molecules (OX-40, LAG-3), inhibition
of signaling pathways involved in cell proliferation (Raf/MAPK/ERK signaling
pathway), or administration of oncolytic viruses. Biological therapy in melanoma has
shown promise in laboratory and clinical studies, with more therapeutic targets to be
revealed as new molecular and cellular mechanisms of the disease are discovered.
 metastatic melanoma, biological therapy, immunotherapy
✓ Biological therapeutic options for melanoma have considerably increased life expectancy

of the patients.
✓ Current therapeutic approaches are related to the tumors associated immunosuppression,

as well as messengers related to cell growth.
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Introduction

Discussions

melanoma or as local therapy, injection in the tumor
after surgical treatment in stage III melanoma with intransit metastasis or satellites without metastatic nodes
(8).
There are several limitations to the use of IL-2 as
immunotherapy. It acts on both effector T cells (Teff)
and on Treg cells, thus having the ability to modulate the
Teff/Treg ratio resulting in either stimulation or
diminution of the immune response. It was
demonstrated that low doses of IL-2 dampen the autoimmune responses by supporting the maintenance of
Treg cells while high doses boost the anti-tumoral
immune responses by stimulating effector T cells. The
amount of cytokine needed for a certain type of immune
response is dictated by the fact that different immune
cells express different types of IL-2 receptors.
Nevertheless, the in vitro effect is hard to translate in
vivo, on laboratory animals and especially on patients.
This may be one reason why IL-2 works only on a
fraction of patients (4, 6). One of the disadvantages is
the toxicity of high-dose therapy. IL-2 stimulates the
production of other cytokines which leads to lymphoid
infiltration and results in a capillary leak syndrome. The
immediate effect is hypovolemia and accumulation of
fluid in the extravascular space. Thus, systemic IL-2 use
is limited to patients with good performance status and
is administered under strict observation (9, 10).

I Cytokines
a) IL-2
IL-2 is a cytokine secreted mainly by antigenstimulated CD4+ T helper cells, but it can also be
secreted by CD8+ T cells, natural killer (NK) cells, NKT
cells, activated dendritic cells (DC), and mast cells. IL2 has pleiotropic effects on the immune system: it is a
trophic factor for lymphocytes, enhances the
proliferation, activation, and differentiation of T
lymphocytes and NK cells, and plays a key role in
immune regulation via its effects on regulatory T cells
(Treg). IL-2 was first termed "T-cell growth factor"
upon its discovery and it revolutionized immunology
research as it was one of the first cytokines tested in
patients and approved to treat cancer. IL-2 was FDA
approved in 1998 for the treatment of metastatic
melanoma (3–6). In a study using high dose (HD) bolus
IL-2 to treat melanoma patients, complete regression of
the tumor was observed in 6.6% of the patients and this
condition was maintained from 12 to more than 148
months. Partial regression was obtained in 15% of the
patients and was maintained from 2 to 35 months (7).
IL-2 therapy is recommended by guidelines as a secondline systemic treatment in metastatic or unresectable

b) IFN-α
Interferons
(IFNs)
are
cytokines
with
immunomodulatory properties. IFNs were first
described for their antiviral effect but recently, it was
discovered that they also play a role in immune
responses to cancer by their effect on dendritic cells.
Dendritic cells are sentinel antigen-presenting cells.
Encountering of DC with tumor antigens leads to their
activation, migration into the lymph nodes, cooperation
with other immune cells, and initiation of the
antitumoral immune response. Type I IFNs (alpha and
beta) promote the activation, migration, and antigenpresentation of DC. Moreover, type I IFNs have direct
effects on tumor cells inducing their death through a
series of intracellular signals and indirect effects on
tumor cells through its anti-angiogenetic function
(11,12). IFN-alpha is recommended by guidelines in (a)
stage IIB and stage IIC melanoma with negative sentinel
lymph node as adjuvant therapy after wide excision of
the tumor, (b) clinical stage III as adjuvant therapy after
wide excision and complete therapeutic lymph node
dissection, and (c) stage III clinical satellite or in-transit
as primary local therapy if the tumor cannot be
surgically removed (8).

Melanoma is one of the most aggressive malignant
tumors. The incidence is on the rise - from 2005 to 2014,
the rate increased by 3% per year among men and
women older than 50, but remained stable among those
younger than age 50. At the same time, given early
diagnosis and therapeutic progress, the 5-year relative
survival rates have also increased from 80% for the
period 1975-1977 to 92% nowadays. Nevertheless, 5year relative survival rate in locally invasive or
metastatic melanoma is 20%, which has led to the
development of therapies which target this last group of
patients (1). The introduction of biological therapy, also
called immunotherapy, in the treatment of melanoma
has shown remarkable results. This outcome is not
surprising since melanoma is considered one of the most
immunogenic tumors. Exposure to ultraviolet
wavelengths promote mutagenesis and formation of
neoantigens which then are recognized as "non-self" by
the host's immune system (2).
Biological therapy can trigger or help the immune
system fight tumoral cells in different ways: (I)
stimulation of non-specific antitumoral response via
cytokines, (II) vaccination, (III) and adoptive
immunotherapy (2, 3).
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II Vaccination
Melanoma vaccines are vaccines containing
tumoral antigens. Despite the significant success of
microbial vaccines, cancer vaccines have demonstrated
relatively little clinical benefit. Amongst the reasons for
this are the difficulty of finding a target antigen and the
capacity of the tumor cells to escape immune
surveillance. Tested vaccines have focused on several
kinds of antigens: (a) tumor lysate, (b) non-mutated self
antigens - shared by tumoral cells, early embryogenetic
cells and healthy cells in low amounts, and (c)
neoantigens - mutated „non-self” antigens expressed
only by tumor cells which can be shared by more
patients or personalized for each patient. Vaccines exist
in 2 main forms: (a) vaccines that comprise the antigen
peptides in their composition, thus initiating the immune
response upon immune cells’ encounter with the antigen
or (b) vaccines can be administered in the form of
dendritic cells loaded with antigen peptides. In this
form, dendritic cells are challenged with the antigen in
vitro, they process the antigen and then are administered
to the patient (13). Murine models, as well as clinical
trials, have demonstrated that vaccines alone are not
sufficient but they can increase the efficiency of other
therapies. For example, gp100 vaccines increase the
efficacy of IL-2 therapy (14).
A recent study used vaccines targeting up to 20
personalized neoantigens per patient following curative
surgical removal in patients with untreated high-risk
melanoma (stage IIIB/C and IVM 1a/b). Four of the six
vaccinated patients had no recurrence at 25 months postvaccination. Two had progressive disease and were
treated with anti-PD-1 therapy (pembrolizumab) which
led to complete tumor regression (15).
III Adoptive immunotherapy
Adoptive immunotherapy is a technique by which
T-cells are harvested from the patient and reinfused into
the patient after expansion in cultures. Cells can be
harvested either (a) in the form of tumor infiltrating
lymphocytes, which are considered antigen-specific or
(b) in the form of peripheral blood mononuclear cells
which are then engineered to become tumor antigenspecific. The technique is based on the fact that T-cell
responses are specific, robust, and have memory,
suggesting that this type of immune response can target
tumor antigens from throughout the body (including
metastasis), promising a therapeutic effect that may last
several years (16).
Adoptive cell therapy trials using T-cells from
tumor-infiltrating lymphocytes show 40-50% response
rates of adoptive T-cell therapy following IL-2 treatment

with a significant proportion of patients alive and free of
disease 3-5 years after the treatment (17).
Considering that T-cells recognize antigens through
interaction between their TCR receptor and the epitope
presented on MHC molecules of the antigen-presenting
cell, several techniques have been developed in order to
genetically engineer TCR to become antigen-specific.
One of the most promising techniques is the
construction of chimeric antigen receptors for T cells
(CAR-T). CAR-T therapy with CD19 as target antigen
used in B-cell malignancies resulted in complete
remission in 50-90% of the patients. Nevertheless,
clinical trials using CAR-T with GD2 as target antigen
on solid tumors, including melanoma, have not
been very promising, being limited by the
immunosuppressive microenvironment of solid tumors.
Moreover, scarcity of tumor-specific antigens in solid
tumors highlights the need to identify new tumorspecific target antigens in melanoma (18, 19).
IV Immune Checkpoint
modulator molecules
a) PD-1 and CTLA-4

inhibitors and immune

T cell activation after encountering a tumor antigen
is a two-step process. Antigen-presenting cells present
the antigen epitope to T-cells on the MHC molecules.
This is the first step towards activation of T cells.
Completion of the activation is done through costimulation, a process that requires interaction between
B7 molecules on the APC and CD28 molecules on the T
cell. Conversely, co-inhibitory signaling occurs between
PD1/PD2 ligand (on APC) and PD-1 receptor (on T
cells) or CTLA4 which competes for B7 binding (20).
Inhibitory molecules are physiologically upregulated
during high antigenic loads in order to limit
immunopathology when the immune system faces
persistent infection. This phenomenon is called immune
exhaustion.
A side effect of this particular physiological
phenomenon is that tumors are also situations with high
loads of antigen which leads to immune exhaustion and
loss of the anti-tumoral effect of T-cells (21). Therefore,
anti-CTLA-4 and anti- PD-1 antibodies block the
inhibition of T-cell activation, restoring the function of
T-cells (20).
A Phase III clinical trial on stage III/IV melanoma
patients comparing nivolumab (anti-PD-1 antibody) and
ipilimumab (anti-CTLA-4 antibody) showed 44%
response and 6.9 months progression-free survival
among patients treated with nivolumab compared to
19%- and 2.8-months progression-free survival among
those treated with ipilimumab. Administration of both
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nivolumab and ipilimumab resulted in higher response are also infected cells will additionally trigger the innate
rates (58%) and survival (11.5 months) (22).
and adaptive immune response. Oncolytic viruses are
Limitations of the treatment include, besides mild genetically engineered in order to decrease their
side effects, severe side effects related to immune pathogenicity and increase their immunogenicity (28–
stimulation such as inflammation pneumonitis, 30).
Talimogene laherparepvec (T-VEC)
interstitial nephritis, colitis, and exacerbation of preT-VEC is the first used oncolytic virus. It is a
existing auto-immune disorders (psoriasis) or onset of
genetically manipulated Herpes Simplex Virus – 1. Due
new ones (diabetes mellitus) (20).
to genetic engineering, the virus is unable to replicate in
b) CD40
normal cells, has completely lost the tropism for
CD40 is a molecule expressed mainly on certain
neurons, and replicates preferentially in tumor cells.
subsets of antigen presenting cells, such as monocytes,
Further changes in its genome have made it possible to
macrophages, and dendritic cells. CD40 ligand (CD40prevent the rapid clearance of the virus, resulting in
L) is expressed on a large number of cell types,
more profound oncolytic effects and making the virus
including activated CD4 T cells, activated B cells,
lose the capacity to avoid the immune response,
memory CD8 T cells, activated natural killer cells,
resulting in a stronger immune response against infected
granulocytes, endothelial cells, and macrophages. CD40
tumor cells. Moreover, T-VEC has inserted in its
ligation has been demonstrated to enhance the capacity
genome copies of the human Granulocyte Macrophageof dendritic cells to present antigens to CD8 T cell
Colony Stimulation Factor gene. Thus, inside a tumor
antigen by increasing the expression of co-stimulatory
cell, the virus replicates and secretes GM-CSF leading
molecules such as CD80 and CD86 and by increasing
to the lysis of the tumor cell which is followed by the
the expression of immunostimulatory cytokines. Thus,
release of tumor antigens, GM-CSF and viruses. GMactivating CD40 has the potential to bridge innate and
CSF release leads to tumor site infiltration with dendritic
adaptive immunity by triggering an antitumor T cell
cells and generation of T cell immune response against
response (23).
infected tumor cells (28–30).
Several CD40 agonists have been developed for use
A phase III clinical trial on patients with unresected
in clinical trials for various types of cancer. CP 870,893
stage IIIB to stage IV melanoma has shown an overall
monoclonal antibody is a CD40 agonist used in a phase
response rate of 26.4% and a median survival rate of
1 clinical trial for recurrent and stage IV melanoma in
23.3 months (29). The encouraging results and the fact
combination with tremelimumab (anti CTLA-4). This
that T-VEC was well tolerated has led to T-VEC being
research is still ongoing and results have not yet been
the first oncolytic virus approved for melanoma therapy
published (23, 24). CP 870, 893 has also been used in
(28).
combination with polyIC: LC TLR-3 ligand, an
e) OX40
immunostimulant and vaccine peptides in a phase 1
OX40 (CD134) is a co-stimulatory molecule on the
clinical study on stage III and Iv melanoma also with antigen presenting cells and its ligand, OX40L (CD252),
unpublished results (25).
is expressed on a variety of cells, mostly activated CD4
c) LAG-3 (Lymphocyte Activation Gene 3)
and CD8 T cells. It increases clonal expansion of
LAG-3 is an immune checkpoint molecule. It has a effector T-cells and generation of memory T-cells
role in antigen processing and presentation via MHC specific for a certain antigen. It also diminishes the
class II protein binding, negative regulation of T cell immunosuppressive effect of T regulatory cells, which
activation and IL-2 biosynthesis, and positive regulation leads to amplification of the immune response (31–33).
Currently, five molecules are being used for
of cytotoxicity through NK cells (26).
In a clinical trial that combined therapy with targeting of OX40. A phase I clinical trial on patients
nivolumab and anti-LAG antibody in patients refractory with metastatic cancers (melanoma, renal cancer,
to previous immunotherapies, the overall response rate prostate cancer, ureteral cancer and cholangiowas 13 %. The results were preliminary, as the clinical carcinoma) showed regression of at least one metastasis
in 30% of the patients (33).
trial is still ongoing (27).
V Therapy based on Raf/MAPK/ERK signaling
d) Oncolytic viruses
Oncolytic viruses have 2 mechanisms of action: (a) pathway inhibition
Raf/MAP-kinase/ERK signaling pathway is a
infection of the tumor cells which results in the direct
killing of tumor cells, and (b) the fact that tumor cells membrane-to-nucleus group of proteins that
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